Aimmune Therapeutics Inc (NASDAQ:AIMT) – Research analysts at Cantor Fitzgerald increased their FY2019 earnings per share estimates for shares of Aimmune Therapeutics in a report issued on Thursday, November 7th, according to Zacks Investment Research. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will earn ($4.11) per share for the year, up from their prior forecast of ($4.20). Cantor Fitzgerald also issued estimates for Aimmune Therapeutics’ FY2020 earnings at ($3.78) EPS.
A number of other research analysts have also recently commented on the company. Wedbush reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research note on Thursday, October 31st. Goldman Sachs Group set a $27.00 target price on Aimmune Therapeutics and gave the company a “hold” rating in a research note on Friday, October 25th. ValuEngine cut Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 29th. Royal Bank of Canada cut their target price on Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, Piper Jaffray Companies set a $60.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 9th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $43.11.
NASDAQ AIMT traded up $0.81 during trading hours on Monday, hitting $29.40. 699,481 shares of the company were exchanged, compared to its average volume of 716,297. The stock has a market cap of $1.84 billion, a PE ratio of -8.01 and a beta of -0.03. The stock has a 50-day moving average price of $27.34 and a 200 day moving average price of $22.23. Aimmune Therapeutics has a 52 week low of $16.95 and a 52 week high of $29.68. The company has a quick ratio of 4.64, a current ratio of 4.64 and a debt-to-equity ratio of 0.33.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.03). During the same period in the prior year, the firm earned ($0.89) EPS.
In other news, CFO Eric Bjerkholt purchased 1,550 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was purchased at an average price of $22.57 per share, for a total transaction of $34,983.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.75% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of Aimmune Therapeutics by 0.7% in the third quarter. Rhumbline Advisers now owns 63,890 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 462 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Aimmune Therapeutics by 1.2% in the third quarter. California State Teachers Retirement System now owns 69,230 shares of the biotechnology company’s stock valued at $1,450,000 after purchasing an additional 827 shares during the period. Virtus ETF Advisers LLC boosted its holdings in shares of Aimmune Therapeutics by 11.2% in the second quarter. Virtus ETF Advisers LLC now owns 13,338 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 1,345 shares during the period. Marshall Wace North America L.P. purchased a new stake in shares of Aimmune Therapeutics in the first quarter valued at approximately $32,000. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Aimmune Therapeutics in the third quarter valued at approximately $38,000. Hedge funds and other institutional investors own 81.82% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.